Lucida Medical and K2Ai partner to strengthen AI-driven prostate cancer diagnostics in Israel
12 November 2025 – Cambridge, UK – Lucida Medical, a company specialised in AI solutions for the prostate cancer pathway, has entered into a strategic partnership with K2Ai, a healthcare technology provider based in Israel. This collaboration will support the integration of Lucida Medical’s AI solution into clinical workflows, and enable physicians to improve diagnostic accuracy and make informed decisions in prostate cancer care.
K2Ai will work closely with healthcare institutions across Israel to deploy Lucida Medical’s solution at key stages of the diagnostic process and deliver more efficient, informed, and patient-centred care.
“As a company leading the field of AI in healthcare in Israel, K2AI’s mission is to bring physicians access to the most innovative technologies worldwide. Prostate MRI is a critical domain, and it was clear to us that we should partner with Lucida – one of the most innovative and leading companies in the global AI market,” said Kfir Kaper, CEO of K2Ai.
Kobi Gelbgeisser, VP of Business Development at K2Ai, added: “Our partnership with Lucida reinforces our vision – enabling physicians in Israel to access advanced tools that streamline the diagnostic process and improve clinical accuracy. We are confident that combining our local expertise with Lucida’s technology will bring meaningful value to the healthcare system and to patients.”
“We are pleased to partner with K2Ai to advance prostate cancer diagnostics in Israel. This collaboration reflects a shared commitment to long-term impact and innovation across the prostate cancer pathway. Our strategic alignment, and K2Ai’s deep understanding of the Israeli healthcare landscape, will help ensure our technology reaches the clinicians and patients who can benefit most.” said Corina Cucuruzac, VP of Marketing & Sales at Lucida Medical.
About Lucida Medical
Lucida Medical is dedicated to advancing prostate cancer care with proven AI solutions. The flagship product, Pi™, automates MRI analysis for precise segmentation, lesion detection, and risk scoring, improving every step of the care pathway. By enhancing efficiency and enabling consistent, high-quality outputs, Pi™, helps ensure accurate diagnoses, timely, appropriate treatment, and better outcomes for every patient.
About K2Ai
K2Ai specializes in integrating proven AI technologies across Israel and other international healthcare markets. The company is committed to transforming medical practices by deploying cutting-edge solutions that enhance decision-making, reduce operational burdens, and alleviate workforce shortages. The team drives transformation by introducing and implementing the most advanced health technologies, ensuring they lead to lasting changes in healthcare practices. This aligns with company’s long-term goals for improved system efficiency and better patient outcomes.
For media inquiries, please contact:
Roberta Belanova